High-quality products
Reliable performance
In Vivo Pharmacodynamic Evaluation of U-2 OS Cell Line Based Bone Cancer (CAT#: STEM-AE-0005-LGZ)
Introduction
Bone tumors are tumors of the bone or its ancillary tissues. There are benign and malignant. Malignant bone tumors, or bone cancers, develop rapidly with poor prognosis and high mortality. Malignant bone tumors are classified as primary and secondary. Malignant tumors from other tissues or organs in the body metastasize to the bone through the blood circulation and lymphatic system as secondary malignant bone tumors. There is also a kind of lesions called tumor-like lesions. Tumor-like lesions do not have the characteristics of tumor cell morphology, but their ecology and behavior are destructive to tumors, which are generally more limited and easy to cure.
Principle
In vivo activity is the gold standard for the evaluation of drug biological activity, and it is the first verification of non-human comprehensive activity. In vivo pharmacodynamic evaluation plays a decisive role in the confirmation of candidate molecules and the screening of clinical target indications, and is an indispensable link in the development of new drugs. We provide a variety of disease animal models including inflammation, immunity, metabolism, etc., to meet the needs of different new drug research and development projects of customers, and accept customized services.
In vivo pharmacodynamic evaluation, as the basic research of new drugs, is carried out on animals. It is to verify the effect of drugs with the comprehensive participation of a number of other factors, and to understand the effect of drugs on a certain part of the body by comparing and analyzing the animal signs, in vitro organs, blood components, histone expression and tissue changes before and after drug administration.
In vivo pharmacodynamic evaluation, as the basic research of new drugs, is carried out on animals. It is to verify the effect of drugs with the comprehensive participation of a number of other factors, and to understand the effect of drugs on a certain part of the body by comparing and analyzing the animal signs, in vitro organs, blood components, histone expression and tissue changes before and after drug administration.
Applications
Bone Cancer
Procedure
1. Disease model construction.
2. Mice dosing.
3. Efficacy monitoring.
4. Biochemical detection of tissue samples.
2. Mice dosing.
3. Efficacy monitoring.
4. Biochemical detection of tissue samples.
Materials
• Sample Type: liquid or powder
Notes
Oncology efficacy Service package:
In vivo syngeneic model
In vivo CDX model
In vivo PBMC humanized model
In vivo transgenic mouse model
In vivo orthotropic or Metastasis tumor model
In vivo syngeneic model
In vivo CDX model
In vivo PBMC humanized model
In vivo transgenic mouse model
In vivo orthotropic or Metastasis tumor model
Other recommended products
-
In Vivo Pharmacodynamic Evaluation of B-hPLAU Mice (Humanized Mice) (CAT#: STEM-AE-0619-LGZ)
-
In Vivo Pharmacodynamic Evaluation of B-hPSCA Mice (Humanized Mice) (CAT#: STEM-AE-0590-LGZ)
-
In Vivo Pharmacodynamic Evaluation of Concanavalin A Induced Liver Injury in Mice (CAT#: STEM-AE-0132-LGZ)
-
In Vivo Pharmacodynamic Evaluation of ACHN Cell Line Based Kidney Cancer (CAT#: STEM-AE-0058-LGZ)
-
In Vivo Pharmacodynamic Evaluation of B-hCD3E/hCD22 Mice (Humanized Mice) (CAT#: STEM-AE-0609-LGZ)
-
In Vivo Pharmacodynamic Evaluation of B-hIL4/hIL4RA Mice (Cytokine Humanized Mice) (CAT#: STEM-AE-0463-LGZ)
-
In Vivo Pharmacodynamic Evaluation of B-hTNFA/hIL17A Mice (Cytokine Humanized Mice) (CAT#: STEM-AE-0464-LGZ)
-
In Vivo Pharmacodynamic Evaluation of B-hCD3E/hMSLN Mice (Humanized Mice) (CAT#: STEM-AE-0650-LGZ)
Wide range of applications
For various laboratory needs
Expert support
Professional service team
Fast delivery
Global shipping